Ceftolozane and Tazobactam for the Treatment of Bacterial Infections: A Review of Clinical Effectiveness, Cost-effectiveness, and Guidelines [Internet].

Health Canada issued a Notice of Compliance for Zerbaxa in September 2015 and the date of first sale was in January 2016. Given the recent introduction of IV ceftolozane/tazobactam into clinical practice, evidence is required to support its broader use and to better understand its place in therapy relative to existing antimicrobial treatment options. The purpose of this report is to evaluate the clinical effectiveness, cost-effectiveness, and evidence-based guidelines for the use of ceftolozane/tazobactam for patients with bacterial infections.

http://ift.tt/2kerOQA